If approved, the acquisition would combine two of the leading makers of heart-related devices. The deal will cost Abbott roughly $25 billion.
For Abbott, the acquisition represents a way for the company to enhance its position in the medical devices business and “gain a better negotiating position” with its hospital customers, according to a NASDAQ report.
Both organizations agreed to the partnership in April. They expect the deal to officially close in the fourth quarter.
More articles about transactions and valuations:
Washington Health System, UPMC strike cardiac surgery partnership
McLeod Heath to acquire Clarendon Health System
Yale New Haven, Lawrence & Memorial deal faces public scrutiny
